253 related articles for article (PubMed ID: 25124953)
21. Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds.
Shields CL; Bianciotto CG; Jabbour P; Ramasubramanian A; Lally SE; Griffin GC; Rosenwasser R; Shields JA
Arch Ophthalmol; 2011 Nov; 129(11):1399-406. PubMed ID: 21670328
[TBL] [Abstract][Full Text] [Related]
22. Intravitreal injection of melphalan for intraocular retinoblastoma.
Suzuki S; Aihara Y; Fujiwara M; Sano S; Kaneko A
Jpn J Ophthalmol; 2015 May; 59(3):164-72. PubMed ID: 25808017
[TBL] [Abstract][Full Text] [Related]
23. Spectral Domain Optical Coherence Tomography Reveals Hidden Fovea Beneath Extensive Vitreous Seeding From Retinoblastoma.
Hasanreisoglu M; Dolz-Marco R; Ferenczy SR; Shields JA; Shields CL
Retina; 2015 Jul; 35(7):1486-7. PubMed ID: 25756924
[No Abstract] [Full Text] [Related]
24. Re: Francis et al.: The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan (Ophthalmology 2015;122:1173-9).
Sahoo N; Tripathy D
Ophthalmology; 2016 Feb; 123(2):e10. PubMed ID: 26802711
[No Abstract] [Full Text] [Related]
25. Hemorrhage as a sign of treatment failure after intra-arterial chemotherapy in retinoblastoma.
Silva RA; Dubovy SR; Hess D; Stratton R; Murray TG
J AAPOS; 2015 Jun; 19(3):268-70. PubMed ID: 25907829
[TBL] [Abstract][Full Text] [Related]
26. Retinoblastoma Control With Primary Intra-arterial Chemotherapy: Outcomes Before and During the Intravitreal Chemotherapy Era.
Shields CL; Alset AE; Say EA; Caywood E; Jabbour P; Shields JA
J Pediatr Ophthalmol Strabismus; 2016 Sep; 53(5):275-84. PubMed ID: 27486728
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study.
Bogan CM; Kaczmarek JV; Pierce JM; Chen SC; Boyd KL; Calcutt MW; Bridges TM; Lindsley CW; Nadelmann JB; Liao A; Hsieh T; Abramson DH; Francis JH; Friedman DL; Richmond A; Daniels AB
Br J Ophthalmol; 2022 Feb; 106(2):288-296. PubMed ID: 33972235
[TBL] [Abstract][Full Text] [Related]
28. [Short-term efficacy of intravitreal injection of melphalan for refractory vitreous seeding from retinoblastoma].
Xue K; Ren H; Zhang R; Yuan YF; Qian J
Zhonghua Yan Ke Za Zhi; 2017 Aug; 53(8):570-574. PubMed ID: 28851196
[No Abstract] [Full Text] [Related]
29. Intra-arterial chemotherapy for advanced retinoblastoma: is the time right for a prospective clinical trial?
Levin MH; Gombos DS; O'Brien JM
Arch Ophthalmol; 2011 Nov; 129(11):1487-9. PubMed ID: 22084219
[No Abstract] [Full Text] [Related]
30. [Superselective intra-arterial chemotherapy with melphalan for retinoblastoma].
Padrón-Pérez N; Català-Mora J
J Fr Ophtalmol; 2014 Feb; 37(2):176. PubMed ID: 24210940
[No Abstract] [Full Text] [Related]
31. TOXICITY AND EFFICACY OF INTRAVITREAL MELPHALAN FOR RETINOBLASTOMA: 25 µg Versus 30 µg.
Liao A; Hsieh T; Francis JH; Lavery JA; Mauguen A; Brodie SE; Abramson DH
Retina; 2021 Jan; 41(1):208-212. PubMed ID: 32106160
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Toxicity of Intravitreous Chemotherapy for Retinoblastoma: Four-Year Experience.
Francis JH; Brodie SE; Marr B; Zabor EC; Mondesire-Crump I; Abramson DH
Ophthalmology; 2017 Apr; 124(4):488-495. PubMed ID: 28089679
[TBL] [Abstract][Full Text] [Related]
33. Stability of melphalan solution for intravitreal injection for retinoblastoma.
Buitrago E; Lagomarsino E; Mato G; Schaiquevich P
JAMA Ophthalmol; 2014 Nov; 132(11):1372-3. PubMed ID: 25078631
[No Abstract] [Full Text] [Related]
34. Alternated intra-arterial and intravitreal chemotherapy for advanced intraocular retinoblastoma: preliminary successful results without systemic chemotherapy.
De Francesco S; Galluzzi P; Bracco S; Menicacci F; Motolese E; Hadjistilianou T
Int Ophthalmol; 2015 Dec; 35(6):887-95. PubMed ID: 26416040
[TBL] [Abstract][Full Text] [Related]
35. Assessment of retinoblastoma RNA reflux after intravitreal injection of melphalan.
Winter U; Nicolas M; Sgroi M; Sampor C; Torbidoni A; Fandiño A; Chantada GL; Munier FL; Schaiquevich P
Br J Ophthalmol; 2018 Mar; 102(3):415-418. PubMed ID: 29089355
[TBL] [Abstract][Full Text] [Related]
36. Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients.
Xue K; Ren H; Meng F; Zhang R; Qian J
BMC Ophthalmol; 2019 Feb; 19(1):61. PubMed ID: 30808420
[TBL] [Abstract][Full Text] [Related]
37. Persistence of retinal function after intravitreal melphalan injection for retinoblastoma.
Brodie SE; Munier FL; Francis JH; Marr B; Gobin YP; Abramson DH
Doc Ophthalmol; 2013 Feb; 126(1):79-84. PubMed ID: 23143758
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal HDAC Inhibitor Belinostat Effectively Eradicates Vitreous Seeds Without Retinal Toxicity In Vivo in a Rabbit Retinoblastoma Model.
Kaczmarek JV; Bogan CM; Pierce JM; Tao YK; Chen SC; Liu Q; Liu X; Boyd KL; Calcutt MW; Bridges TM; Lindsley CW; Friedman DL; Richmond A; Daniels AB
Invest Ophthalmol Vis Sci; 2021 Nov; 62(14):8. PubMed ID: 34757417
[TBL] [Abstract][Full Text] [Related]
39. Comparison of intravitreal melphalan with and without topotecan in the management of vitreous disease in retinoblastoma.
Kiratli H; Koç I; Öztürk E; Varan A; Akyüz C
Jpn J Ophthalmol; 2020 Jul; 64(4):351-358. PubMed ID: 32447585
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of intravitreal injections of melphalan in the treatment of retinoblastoma vitreous seeding.
Cieślik K; Rogowska A; Danowska M; Hautz W
Adv Clin Exp Med; 2024 Feb; 33(2):119-125. PubMed ID: 37260052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
